Compare NLY & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NLY | NBIX |
|---|---|---|
| Founded | 1996 | 1992 |
| Country | United States | United States |
| Employees | 212 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3B | 13.2B |
| IPO Year | N/A | 1996 |
| Metric | NLY | NBIX |
|---|---|---|
| Price | $21.87 | $158.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 22 |
| Target Price | $23.82 | ★ $180.91 |
| AVG Volume (30 Days) | ★ 5.1M | 1.1M |
| Earning Date | 04-21-2026 | 05-05-2026 |
| Dividend Yield | ★ 12.42% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | N/A | ★ 1.91 |
| Revenue | N/A | ★ $161,626,000.00 |
| Revenue This Year | $188.83 | $24.73 |
| Revenue Next Year | $2.40 | $13.14 |
| P/E Ratio | ★ $7.88 | $81.92 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $18.58 | $121.83 |
| 52 Week High | $24.52 | $162.39 |
| Indicator | NLY | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 47.86 | 70.80 |
| Support Level | $21.38 | $133.96 |
| Resistance Level | $22.29 | $160.08 |
| Average True Range (ATR) | 0.32 | 4.01 |
| MACD | -0.02 | -0.31 |
| Stochastic Oscillator | 46.74 | 69.93 |
Annaly Capital Management Inc is an American mortgage real estate investment trust. Its business objective is to generate net income for distribution to its stockholders and optimize its returns through prudent management of its diversified investment strategies. The company's reportable operating segments are: the Agency segment, which invests in Agency mortgage-backed securities collateralized by residential mortgages; the Residential Credit segment, which invests in non-Agency residential whole loans and securitized products within the residential and commercial markets; the Mortgage Servicing Rights segment; and Corporate & Other. Maximum revenue for the company is generated from its Agency segment.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.